Targets › CD80
5 programs from 4 companies in 62 trials: 31 Phase 2, 18 Phase 1, 8 Phase 3, 5 Phase 4; Oncology, Genitourinary, Immunology; next expected readout Nov 2026.
Costimulatory molecule that belongs to the immunoglobulin superfamily that plays an important role in T-lymphocyte activation. Acts as the primary auxiliary signal augmenting the MHC/TCR signal in naive T-cells by acting as a ligand for the CD28 receptor which is constitutively expressed on the cell surface of T-cells. (UniProt, P33681)
Open in Phaseline: the race on CD80, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| University of Pennsylvania | 2-[18F]-FA Voltage-gated calcium channel modulator | CHRNA4, OPRK1, OPRD1, OPRM1, UL51, ADRA2A, ADRA2C, ADRA2B, Ion channels, CACNB4, CACNB2, CACNB1, CACNB3, TNF, SLC6A4, HTR2A, HTR2C, FKBP1A, CD86, CD80, PDE4A, PDE4D, PDE4B, PDE4C, PDE3A, CHRNB2, STN | Phase 4 | Alcohol Use Disorder; Acute Kidney Injury; Insomnia; Giant Cell Arteritis … | Nov 2026 |
| Bristol-Myers Squibb | Abatacept T-lymphocyte activation antigen CD86 inhibitor; T-lymphocyte activation antigen CD80 inhibitor | CD86, CD80 | Phase 3 | Rheumatoid Arthritis; Myocarditis Acute; Polyarticular Course Juvenile Idiopathic Arthritis (JIA); Biphenotypic Acute Leukemia … | Sep 2027 |
| Bristol-Myers Squibb | Belatacept T-lymphocyte activation antigen CD86 inhibitor; T-lymphocyte activation antigen CD80 inhibitor | CD86, CD80 | Phase 3 | Renal Allograft Recipients; Kidney Diseases; Chronic Kidney Failure; Heart Transplantation … | Dec 2032 |
| Coya Therapeutics | COYA 302 Low-dose IL-2 to enhance regulatory T cell function combined with abatacept (CTLA-4 Ig) to | IL2, CD80, CD86 | Phase 2 | Amyotrophic Lateral Sclerosis (ALS) | Apr 2027 |
| GI Innovation | GI-102 CD80-IgG4 Fc-IL2v3 fusion protein | CD80 | Phase 2 | Cancer Survivors; Advanced Solid Tumor; Metastatic Castration-resistant Prostate Cancer (mCRPC) | Apr 2027 |
Rheumatoid Arthritis (4) Graft Vs Host Disease (3) Sickle Cell Disease (3) Cancer Survivors (2) Kidney Transplant (2) Alcohol Use Disorder (2) Head and Neck Squamous Cell Carcinoma (2) Advanced Solid Tumor (1) Metastatic Castration-resistant Prostate Cancer (mCRPC) (1) Amyotrophic Lateral Sclerosis (ALS) (1) Myocarditis Acute (1) Polyarticular Course Juvenile Idiopathic Arthritis (JIA) (1)
small molecule (3), mixed (2)
Bristol-Myers Squibb (2) GI Innovation (1) Coya Therapeutics (1) University of Pennsylvania (1)
CD86 (4) IL2 (1) CHRNA4 (1) OPRK1 (1) OPRD1 (1) OPRM1 (1) UL51 (1) ADRA2A (1) ADRA2C (1) ADRA2B (1) Ion channels (1) CACNB4 (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.